{"id":{"repo_id":"toronto-retro","oai_identifier":"oai:utoronto.scholaris.ca:1807/67621"},"canonical_url":"https://search.dev.ndltd.org/etd/toronto-retro/oai:utoronto.scholaris.ca:1807/67621","repository":{"repo_id":"toronto-retro","name":"University of Toronto","base_url":"https://utoronto.scholaris.ca/server/oai/request"},"display":{"title":"Role of the Vitamin D Receptor in MDR1/P-glycoprotein Regulation at the Blood-brain Barrier","abstract":"The blood-brain barrier (BBB) presents a major obstacle for drugs targeting the brain. Drugs that are small or lipophilic enough can penetrate the physical barrier, but are commonly effluxed back into the blood by transporters that are expressed at the luminal membrane, notably P-glycoprotein (P-gp). It has also been shown that amyloid-β (Aβ), a key player in Alzheimer's disease, is a P-gp substrate. We demonstrate that P-gp levels and function are upregulated upon activation by the vitamin D receptor (VDR) via its natural ligand 1α,25-dihydroxyvitamin D","abstract_html":"The blood-brain barrier (BBB) presents a major obstacle for drugs targeting the brain. Drugs that are small or lipophilic enough can penetrate the physical barrier, but are commonly effluxed back into the blood by transporters that are expressed at the luminal membrane, notably P-glycoprotein (P-gp). It has also been shown that amyloid-β (Aβ), a key player in Alzheimer's disease, is a P-gp substrate. We demonstrate that P-gp levels and function are upregulated upon activation by the vitamin D receptor (VDR) via its natural ligand 1α,25-dihydroxyvitamin D","abstract_has_math":false,"creators":["Durk, Robert Matthew"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Pharmaceutical Sciences","school":null,"contributors":[],"advisors":["Pang, Kim-Ching Sandy"],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-06","date_published":"2014-06","updated_at":"2026-07-27T21:28:01Z","subjects":["blood-brain barrier","P-glycoprotein","regulation","vitamin D receptor"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/1807/67621","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Pang, Kim-Ching Sandy"]},{"key":"dc:contributor.department","label":"Department","values":["Pharmaceutical Sciences"]},{"key":"dc:creator","label":"Author","values":["Durk, Robert Matthew"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2015-02-13T16:42:30Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2015-02-13T16:42:30Z"]},{"key":"dc:date.issued","label":"Date","values":["2014-06"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["blood-brain barrier","P-glycoprotein","regulation","vitamin D receptor"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/1807/67621"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The blood-brain barrier (BBB) presents a major obstacle for drugs targeting the brain. Drugs that are small or lipophilic enough can penetrate the physical barrier, but are commonly effluxed back into the blood by transporters that are expressed at the luminal membrane, notably P-glycoprotein (P-gp). It has also been shown that amyloid-β (Aβ), a key player in Alzheimer's disease, is a P-gp substrate. We demonstrate that P-gp levels and function are upregulated upon activation by the vitamin D receptor (VDR) via its natural ligand 1α,25-dihydroxyvitamin D"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Ph.D."]},{"key":"dc:title","label":"Title","values":["Role of the Vitamin D Receptor in MDR1/P-glycoprotein Regulation at the Blood-brain Barrier"]}]}],"canonical_facts":{"dc:contributor.advisor":["Pang, Kim-Ching Sandy"],"dc:contributor.department":["Pharmaceutical Sciences"],"dc:creator":["Durk, Robert Matthew"],"dc:date.accessioned":["2015-02-13T16:42:30Z"],"dc:date.available":["2015-02-13T16:42:30Z"],"dc:date.issued":["2014-06"],"dc:description.abstract":["The blood-brain barrier (BBB) presents a major obstacle for drugs targeting the brain. Drugs that are small or lipophilic enough can penetrate the physical barrier, but are commonly effluxed back into the blood by transporters that are expressed at the luminal membrane, notably P-glycoprotein (P-gp). It has also been shown that amyloid-β (Aβ), a key player in Alzheimer's disease, is a P-gp substrate. We demonstrate that P-gp levels and function are upregulated upon activation by the vitamin D receptor (VDR) via its natural ligand 1α,25-dihydroxyvitamin D"],"dc:description.degree":["Ph.D."],"dc:identifier.uri":["http://hdl.handle.net/1807/67621"],"dc:subject":["blood-brain barrier","P-glycoprotein","regulation","vitamin D receptor"],"dc:title":["Role of the Vitamin D Receptor in MDR1/P-glycoprotein Regulation at the Blood-brain Barrier"],"dc:type":["Thesis"]},"updated_at":"2026-07-27T21:28:01Z"}